Modulation of activity of proneurotrophins

摘要

The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.

主权项

1. A method of treating a neurological disease or a neural disorder comprising administering to a subject in need thereof a therapeutically effective amount of an antibody that binds to:
(1) residues 7-10 (RIFR); (2) residues 14-18 (FAKNF); or (3) residues 7-10 (RIFR) and residues 14-18 (FAKNF); of a Sortilin receptor that consists of the amino acid sequence of SEQ ID NO:25, wherein: (i) said antibody inhibits binding of a pro-neurotrophin to a binding site on said Sortilin receptor, thereby treating said neurological disease or neural disorder; and (ii) said neurological disease or neural disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's chorea, stroke, nerve deafness, peripheral neuropathy, and Fabry's disease.